Zimmer Biomet Holdings Inc (ZBH) 시세

Zimmer Biomet Announces Definitive Agreement to Acquire Paragon 28

WARSAW, Ind. and ENGLEWOOD, Colo., Jan. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Paragon 28, Inc. (NYSE: FNA), a leading medical device company focused exclusively on the foot and ankle orthopedic segment, today announced they have entered into a definitive agreement for Zimmer Biomet to acquire all outstanding shares of common stock of Paragon 28 for an upfront payment of $13.00 per share in cash, corresponding to an equity value of approximately $1.1 billion and an enterprise value of approximately $1.2 billion. Paragon 28 shareholders will also receive a non-tradeable contingent value right (CVR) entitling the holder to receive up to $1.00 per share in cash if certain revenue milestones are achieved. The CVR will be payable in whole or in part if net sales exceed $346 million up to $361 million (with the CVR payments calculated linearly between $0.00 and $1.00 if net sales are between $346 million and $361 million) during Zimmer Biomet's fiscal year 2026. The board of directors of each of Zimmer Biomet and Paragon 28 has unanimously approved the proposed transaction.

https://investor.zimmerbiomet.com/news-and-events/news/2025/01-28-2025-225939148

========================================

For continued coverage of significant Airplane malfunctions and why Sintx Si3N4 aerospace products are needed goto my research board. 42 passenger plane malfunctions since December 22nd...
https://investorshub.advfn.com/Bostons-research-43724

Here is a collection of my research going over multiple subjects including Sintx connections with Zimmer Biomet, Solventum, Morgan Ceramics, & NP Aerospace. Includes other research topics as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175357996

ZBH 3Q24 results:

https://finance.yahoo.com/news/zimmer-biomet-announces-third-quarter-103000900.html

I wonder what percent growth ZB would be experiencing if it hadnt reduced its revenue by billion a year spinning off ZimVie first?

========================================

Here is a collection of my research going over multiple subjects including Sintx connections with Zimmer Biomet, Solventum, Morgan Ceramics, & NP Aerospace. Includes other research topics as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175270333

You should research Dr Pezzotti. He was a scientist that did several studies for Biomet before joining Sintx in 2015. Hes been integral in development and testing of Si3n4 as well as a consultant for a study testing Sintx Si3n4 femoral heads against Biomets E1 liner in 2016; a decade after the last time these two companies tested their femoral head and liners together. This is an example of strategic parntership where you share resources and Dr Pezzotti is a major resource. Even recently Knighted in Italy for his contributions.

Some of Dr. Pezzotti's Biomet research for Biomet:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174052660

========================================

Sintx 2016 10k

Together with a strategic partner, we have initiated biomechanical testing of our solid silicon nitride femoral heads. The results of this test will be released in 2017
This quote indicates the results of testing of their femoral head with a strategic partner will be released in 2017.
Those results were released testing Sintx Femoral head against Biomet's E1 liners. Thus Zimmer Biomet, or any of its subsidiaries, is Sintx strategic partner in this testing.

Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research
These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology.

Quote Sources:

https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1
2016 10-k pg 13: https://www.sec.gov/Archives/edgar/data/1269026/000149315217010752/form10-k.htm
2017 results: https://ir.sintx.com/news-events/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear
https://web.archive.org/web/20240408152758/https://sintx.com/wp-content/uploads/2021/03/Investor-Call-Transcript-033021.pdf

I should add that the current Chairman, former CEO, was a member of Zimmers surgeon panel from 2002-2014+ (dont know when or if he ever stopped being part of Zimmers panel.
He joined Sintx clinical advisory panel end of 2005. That femoral head-liner study in 2007 would have occurred in 2006 just after Dr Bal joined Sintx, then Amedica. Almost as if Zimmer sent him to Amedica to help develop/give advice for testing hip/knee implants using...Biomet IP it seems. That move didnt make sense back then but obviously post merger it does.

Dr. Sonny Bal, MD

Designer Surgeon Panel, Zimmer Inc., Warsaw, Indiana, 2002 to present.

Total Joint Reconstruction Clinical Advisory Panel, Amedica Inc., Salt Lake City, UT, 2005 to present.
Zimmer Holdings, Inc.: “Comparison of tissue-engineered osteochondral grafts fabricated with mesenchymal stem cells and trabecular metal or allograft bone.” $125,406.00. 5/25/2006 to 5/24/2007.
Zimmer Holdings,Inc.: “Design and testing of a canine biological femoral head replacement.” $342,837.00. 7/1/2011 to 6/30/2014.
https://web.archive.org/web/20240316192627/https://hipandknee.com/wp-content/uploads/2014/04/Dr.-Bal-CV.pdf

The stock is heavily manipulated. There are some hedge funds that have been targeting the stock with a short and distort campaign for about 9 years now. I post about that on Sintx board if you want more info on that.
The stock is not a reflection of the IP however. In fact the better Sintx does, the worse the stock performs because of those funds, in part. Go figure.

Si3n4 is a material that Zimmer & Biomet have been working with for going on 20 years so this isnt just "biotech". Its specific to ZB. For instance:

2007 (ORS Annual Meeting Feb 11-14)

THERMAL CONDUCTIVITY OF FEMORAL BALL STRONGLY INFLUENCED UHMWPE WEAR IN A HIP SIMULATOR STUDY
Ten 28 mm ID isostatically moulded UHMWPE liners were investigated: GUR 1050 resin, gamma-sterilized with 25ñ40 kGy in argon (ArComô, Biomet Inc, Warsaw, IN). The liners were coupled with zirconia (Y-ZrO 2 : ProzyrÆ), cobalt-chrome (Biomet, Inc), silicon nitride (Si3 N 4 : Amedica-Inc, UT) and alumina femoral balls (Al2 O 3 : Biolox-forteÆ) (Figure 1).
Acknowledgements The authors thank Amedica, Utah, US and Biomet Inc, US for their support
Amedica became SinTx when it expanded from just ortho industry.

Quote Source:
http://c.eqcdn.com/_5c7526ae538a6086a4025ef13f5136d2/amedica/db/265/660/pdf/0278.pdf

I'm curious about anything pertaining to biotech. If you don't know the reason for the selloff, just say so.

Just curious why you're more interested in the stock than the IP in relation to Zimmer Biomet?

That has nothing to do with the companies IP.What does today's SINT selloff have to do with, IYO?

That has nothing to do with the companies IP. I was just showing you why Zimmer Biomet would want the IP. It can be used on just about any material currently being used in the ortho/dental markets to bring its benefits to those materials. ZTA, Metals, PEEk, Si3n4 can imbue those materials with antimicrobial properties as well as enhance their osseointegration. Something not mentioned in the PR was the fact that coatings should reduce metal ion release into the body like indicated in this previous PR.

Composite Coating of PEKK + Silicon Nitride Successfully Applied to Ti-Alloy Substrate; Product to Address Infection Risk, Metallosis, & Bone Integration
https://ir.sintx.com/news-events/press-releases/detail/236/sintx-receives-notice-of-allowance-for-united-states-patent

Without coatings this happens:


https://i.imgur.com/nLg7SXT.jpg

Why is SINT down 20% today?

announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application no. 17/634,141 entitled "Methods of Surface Functionalization of Zirconia-Toughed Alumina with Silicon Nitride Ceramic.”

The patent covers novel methods of bonding bioactive silicon nitride or mixtures of silicon nitride and bioactive glass to zirconia-toughened alumina (ZTA) and similar material surfaces. This invention is designed to impart silicon nitride’s beneficial biomedical properties, namely improved osseointegration and resistance to bacterial colonization, to relatively biologically inert ZTA substrates, positioning SINTX at the forefront of medical device biomaterial manufacturing.

When compounded with or applied to the surface of conventional inert biomaterials, silicon nitride’s improved osseointegration and resistance to bacterial colonization can be conferred to the resulting device. Another benefit of the coating method is that it allows for potential refinishing of existing devices to upgrade their functionality. Other filings in progress protect similar approaches to applying silicon nitride to metallic and polymeric substrates as part of SINTX’s broader strategy of expanding the applications where silicon nitride’s benefits can be realized.
More reasons for Zimmer Biomet to want this IP.

https://ir.sintx.com/news-events/press-releases/detail/236/sintx-receives-notice-of-allowance-for-united-states-patent

ZBH acquires—(private)—AI-driven surgical-guidance company_for_undisclosed_price:

https://investor.zimmerbiomet.com/news-and-events/news/2024/08-07-2024-113056395 Zimmer Biomet Holdings…today announced that it signed a definitive agreement to acquire OrthoGrid Systems, Inc., (OrthoGrid) a privately-held medical technology company focused on artificial intelligence (AI)-driven surgical guidance systems for total hip replacement. The acquisition includes OrthoGrid's AI-powered, fluoroscopy-based surgical assistance platform Hip AI, as well as two additional FDA-cleared orthopedic applications and over 40 patents.

ZBH reports 2Q24 results:

https://investor.zimmerbiomet.com/news-and-events/news/2024/08-07-2024-113041683

2Q24 results

• Revenue of $1.94B, +6% YoY in constant currency (+4% YoY in US dollars).

• GAAP EPS of $1.18, up from $1.00 in 2Q23.

• Non-GAAP* EPS of $2.01, up from $1.82 in 2Q23.


Updated 2024 guidance

• YoY sales growth of 5-6% in constant currency, unchanged from the guidance given three months ago.

• A (1.0%) sales headwind from exchange rates due to a stronger US dollar than anticipated in the prior guidance. I.e. YoY sales growth in US dollars is now expected to be 4-5% rather than the prior guidance of 4.5-5.5%.

• Non-GAAP* EPS of $8.00-8.15 (up from the actual $7.55 in 2023), which is unchanged from the guidance given three months ago.


2024-2027 guidance from 5/29/24 Investor Day (#msg-174509651)

• YoY sales growth of 4-6% (excluding exchange rates), equal to or slightly higher than the overall med-device market.

• YoY growth of non-GAAP* EPS at least 1.5 times the YoY sales growth (i.e. at least 6-9%).

*Non-GAAP EPS excludes restructuring costs.

Read the study see if you think the material good as I do and can help liven up the ortho industry.

Who makes that?

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application


https://www.mdpi.com/2571-6131/4/2/16/htm

Which one?

Yep 1 material.

You last two posts speak of a material (singular), implying that there is one specific substance you have in mind. Is this true?

Because it can be imbued and coated on other implants, Zimmer, if it acquired the tech one day, could make a lot of money licensing it out to other ortho companies.

Not to mention the material would help Zimmer diversify its portfolio as it can be used outside of ortho.

A biomaterial that bring with it several benefits over current materials. For instance, biodegradable and thus instead of accumulating in the body tissue/organs the way metals and plastic do, can be excreted.
A material that not not only resists bacteria but kills it to help prevent implant infections.
A material thats osteointegrative that should improve bone integration to prevent implant rejection.
A material that can be imbued into PEEK or used as a coating for metals so it can enhance current materials already in use in ortho/dental.

The added benefits should allow companies to increase pricing over older tech.

Zimmers been aware of this material for sometime. It needs to step up its partnership and expand their R&D efforts around this material already.

Can you elaborate?

New ortho material could change that.

ZBH’s new real-estate venture:

https://finance.yahoo.com/news/zimmer-biomet-outlines-strategy-deliver-210200055.html Zimmer Biomet also announced today that it has formalized a partnership with CBRE Group, Inc. (NYSE: CBRE), the world's largest commercial real estate services and investment firm, to develop and outfit orthopedic ambulatory surgery centers (ASC) in the U.S. This strategic alliance will leverage the companies' respective core strengths as leaders in healthcare technology and commercial real estate services to deliver the latest in medical technology to more patients across the country. The partnership offers a comprehensive, turnkey solution to surgeons and institutions looking to expand their orthopedic ASC footprint. The point of all this is that orthopedic surgeries cost less when done in ASCs than when done in hospitals.

Once upon a time—(~15-20 yrs ago)—medical devices were a hot growth area. Now the sector is growing at barely more than the rate of US price inflation.

ZBH issues 2024-2027 guidance:

https://finance.yahoo.com/news/zimmer-biomet-outlines-strategy-deliver-210200055.html
• Mid-single-digit percentage constant currency-consolidated [i.e. excluding FX] of revenue compound annual growth rate (CAGR)

• Adjusted [non-GAAP] earnings per share (EPS) growth at least 1.5 times revenue growth [i.e. 6-9%]

• Free Cash Flow1 growing at least 100 basis points faster than adjusted EPS ZBH says the overall medical-device market is growing revenue at 4% per annum, so ZBH’s mid-single-digit revenue-growth guidance for 2024-2027 is slightly above the market’s own growth rate.

ZBH expects that its entire growth rate will come from volume and mix rather than price increases.

ZBH Investor Day slides:

https://investor.zimmerbiomet.com/~/media/Files/Z/ZimmerBiomet-IR/reports-and-presentations/zbh-ir-day-deck-5-29-24.pdf

ZBH 1Q24 CC transcript:

https://finance.yahoo.com/news/zimmer-biomet-holdings-inc-nyse-165742036.html

ZBH reports 1Q24 results—reiterates 2024 guidance:

https://finance.yahoo.com/news/zimmer-biomet-announces-first-quarter-103000875.html

2024 guidance remains non-GAAP EPS of $8.00-8.15; constant-currency YoY revenue growth of 5-6%; and a negative 0.5% hit to YoY sales growth from exchange rates.

ZBH reports 4Q23 results—issues 2024 guidance:

https://investor.zimmerbiomet.com/~/media/Files/Z/ZimmerBiomet-IR/press-release/zimmer-biomet-press-release-q4-2023.pdf

2024 guidance for revenue growth is +5-6% YoY in constant currency and +4.5-5.5% in USD.

2024 non-GAAP EPS guidance is $8.00-8.15. At the current share price (~$123), the midpoint of the guidance range represents a forward EPS of ~15x.

Note: ZBH’s non-GAAP EPS excludes restructuring costs, which were $61.2M ($0.29/sh) in 4Q23. I object to this policy for companies such as ZBH who are in a restructuring mode continually.

Independent director bought $225K of stock on the open market last week:

https://www.sec.gov/Archives/edgar/data/1136869/000106299323020641/xslF345X05/form4.xml

Re: GLP-1 effect on med-device companies

ZBH’s new CEO concurs with the discussion in #msg-173002788; from the 3Q23 CC transcript:

https://finance.yahoo.com/news/zimmer-biomet-holdings-inc-nyse-224434890.html …once the cartilage is damaged, there is no recovery. …dropping weight is not going to cure osteoarthritis. …If anything, obesity is a blocker today to joint surgery as many surgeons are uncomfortable operating on patients with a BMI greater than 40 [in some countries] or even above the 30 threshold in some locations.

So why could GLP-1s then be a tailwind for orthopedics? Three compelling reasons. First, if you can lower the patient’s BMI below a certain threshold… these patients now become eligible for surgery. And all the data points that we’re getting in primary markets like the U.S. is that there is a large percentage of patients who today are not going through surgery because their BMI is too high.

Secondly, if a patient does lose…weight…and…become more active, there will be a greater risk for additional joint procedures because there will be injury.

And third, if a patient loses weight, they are likely to live longer… expanding the patient’s [timeline] for an orthopedic procedure. A good example of this is Japan, the second-largest market in the world for osteoarthritis with minimal obesity rates, but very long life expectancy...

ZBH 3Q23 CC transcript:

https://finance.yahoo.com/news/zimmer-biomet-holdings-inc-nyse-224434890.html

ZBH reports 3Q23 results—reiterates 2023 non-GAAP-EPS guidance:

https://investor.zimmerbiomet.com/news-and-events/news/2023/11-07-2023-113117335

3Q23 revenue was $1.754 billion, +4.7% YoY in constant currency.

3Q23 GAAP EPS was $0.77, down from $0.92 in 3Q22.

3Q23 non-GAAP EPS (which excludes restructuring costs) was $1.65, up from $1.58 in 3Q22.

ZBH reiterated 2023 non-GAAP EPS guidance of $7.47-7.57, despite a larger than previously expected hit from foreign currency.

ZBH 3Q23 CC 11/7/23 8:30am ET.

ZBH CEO will become CEO of 3M’s healthcare spinoff:

https://finance.yahoo.com/news/bryan-hanson-named-ceo-3ms-122300047.html

https://finance.yahoo.com/news/zimmer-biomet-announces-leadership-transition-122000860.html

ZBH 2Q23 CC transcript:

https://finance.yahoo.com/news/zimmer-biomet-holdings-inc-nyse-103206455.html

ZBH reports 2Q23 results—shares fall despite raised 2023 guidance:

https://investor.zimmerbiomet.com/news-and-events/news/2023/08-01-2023-113054956

https://finance.yahoo.com/news/medical-device-maker-zimmer-biomet-122133634.html Zimmer Biomet Holdings on Tuesday raised its full-year profit forecast after beating second-quarter estimates on demand for its medical devices but shares fell [about 4%] as investors focused on the company's comments for 2024.

… The company said it expects backlog to remain the same or decrease going into 2024.

… The company now expects full-year profit of $7.47 to $7.57 per share, compared with its previous forecast of $7.40 to $7.50.

Medical-device stocks (including ZBH) are strong today, while health-insurance stocks (e.g. HUM) are weak. Somebody apparently just realized that elective-procedure volumes are back to pre-pandemic levels and growing.

Actually, there is no scientific evidence to support the claim that titanium blood serum levels increase by 3.5fold within one year of implantation. While titanium is commonly used in medical implants due to its biocompatibility, there is no known mechanism by which titanium implants can directly influence blood serum levels.

Titanium implants are known to integrate with surrounding tissues through a process called osseointegration, where the bone fuses with the implant. This integration occurs on a structural level, facilitating the stability and longevity of the implant. However, it does not lead to a significant alteration in blood serum composition or titanium levels within the bloodstream.

It's important to approach such claims with a critical mindset and rely on scientific studies and empirical evidence. While titanium implants have proven benefits in terms of their mechanical properties and compatibility with the human body, attributing miraculous serum level increases to titanium implants is unsupported by scientific research.

Remember, it's always best to consult reliable scientific sources and experts in the field when evaluating medical claims to ensure accurate and evidence-based information.

Did you know titanium bloodserum levels increase 3.5fold, on average, within 1 year of implantation?

While it is true that there are articles discussing potential adverse reactions to titanium (Ti) or its corrosive by-products, it's important to consider the overall scientific consensus and the weight of the evidence.

While a small subset of individuals may experience hypersensitivity or allergic reactions to certain metals, including titanium, these cases are relatively rare. The vast majority of individuals tolerate titanium implants without any adverse reactions or complications. Titanium has been extensively used in medical and dental applications for many years due to its biocompatibility and corrosion resistance.

It is crucial to differentiate between potential rare reactions in specific individuals and the general safety and effectiveness of titanium implants. The scientific and medical communities have thoroughly studied the biocompatibility and safety of titanium and its alloys. These studies have consistently shown that titanium implants have a high success rate and low incidence of adverse reactions in the general population.

It is important to approach scientific research with critical thinking and consider the overall body of evidence. While individual studies may highlight specific cases or potential concerns, they should be weighed against the larger body of research and scientific consensus. It is always recommended to consult with qualified healthcare professionals who can provide personalized advice based on individual circumstances and medical history.

"There are many published articles supporting these views, but there is recent scientific evidence that Ti, or its corrosive by-products, may cause harmful reactions in humans. It is important for all medical and dental professionals to understand the implications, complexities, and all potential pathways of exposure to this metal"

While it is true that some patients may experience less severe immune reactions to titanium implants, it is important to note that titanium is widely recognized as a biocompatible material with a low incidence of allergic reactions. The majority of individuals tolerate titanium implants well without any adverse effects.

Allergic reactions to titanium are considered extremely rare, and when they do occur, they tend to be localized and mild. The immune response to titanium implants is generally minimal, as titanium forms a protective oxide layer on its surface that helps prevent corrosion and immune reactions.

It is also worth mentioning that the medical field has rigorous testing and screening protocols in place to identify potential allergies or sensitivities before implanting any medical devices, including titanium implants. These pre-implantation tests, such as patch testing and laboratory investigations, help to identify individuals who may have a higher risk of adverse reactions to certain materials.

While it is possible for some patients to develop delayed sensitivities or immune reactions to titanium implants over time, it is crucial to approach such claims with scientific evidence and peer-reviewed studies. Without robust research demonstrating a widespread problem of undetected titanium allergies leading to various health issues, it would be speculative to attribute unrelated symptoms solely to titanium implants.

If individuals have concerns about their implants or suspect an allergic reaction, it is recommended to consult with healthcare professionals who can conduct proper medical evaluations and provide appropriate advice based on individual circumstances.

What makes it worse is alot of patients are having less severe immune reactions to titanium and thus do not know or pursue it. Blaming the problem on something else.

While it is true that some individuals may develop sensitivities or allergic reactions to certain materials over time, such as titanium implants, it is essential to consider the available scientific evidence and expert opinions on the matter.

When it comes to titanium implants, such as those used in dental or orthopedic procedures, allergic reactions are extremely rare. Titanium is known for its biocompatibility, meaning it is generally well-tolerated by the human body and does not typically trigger immune responses or sensitivities. Titanium implants have been extensively used for many years with a high success rate and minimal adverse reactions reported.

Allergic reactions to titanium are considered uncommon, and when they do occur, they are often associated with pre-existing allergies to other metals, such as nickel or cobalt, which may be present as impurities in the titanium alloy. In such cases, it is crucial for patients to inform their healthcare providers about any known metal allergies before undergoing implant procedures.

Furthermore, thorough pre-implant testing and evaluation are typically conducted to identify potential sensitivities or allergies. This includes assessing a patient's medical history, conducting skin patch tests, and utilizing other diagnostic techniques to determine the suitability of titanium implants. These measures help to minimize the risk of adverse reactions and ensure the best possible outcome for patients.

It is important to rely on scientifically sound studies, expert opinions, and medical guidelines when evaluating the safety and potential risks associated with medical implants. While anecdotal reports and individual experiences can provide valuable insights, they should be interpreted with caution and considered in the context of broader scientific knowledge and consensus.

Not true. People are testing and show no initial response but after having the implant for months to years, patients are developing sensitivities.

The problem is you'll never know who is going to be sensitive and its a growing problem.

Allergic reactions to titanium implants are extremely rare, and with proper testing, it is easy to identify individuals who are sensitive to titanium.

Biocompatibility of Titanium:

Titanium is widely recognized as a biocompatible material, meaning it is well-tolerated by the human body. When titanium implants are surgically placed, they generally integrate smoothly with the surrounding tissues without triggering an immune response. The biocompatibility of titanium is attributed to its oxide layer, which forms naturally upon exposure to oxygen. This oxide layer acts as a protective barrier, preventing direct contact between the titanium metal and body tissues, minimizing the risk of allergic reactions.

Low Reactivity and Corrosion Resistance:

Titanium exhibits excellent corrosion resistance, ensuring the stability and longevity of implants within the body. Unlike other metals, titanium does not easily corrode or release metal ions into the surrounding tissues. This low reactivity reduces the likelihood of an immune response, minimizing the risk of allergic reactions. The stable nature of titanium implants further contributes to their biocompatibility and the rarity of adverse reactions.

Lack of Allergenic Potential:

Titanium is considered to have low allergenic potential, meaning it does not commonly elicit allergic responses in individuals. The structure and properties of titanium do not typically trigger the immune system's sensitization process, which is necessary for an allergic reaction to occur. Unlike certain metals, such as nickel or cobalt, titanium has a significantly lower sensitization rate. This inherent low allergenic potential of titanium makes allergic reactions to titanium implants highly uncommon.

Minimal Reports of Allergic Reactions:

The medical literature contains very few documented cases of true allergic reactions specifically attributed to titanium implants. The reported cases are exceedingly rare, and most of them involve individuals with pre-existing metal allergies or hypersensitivity conditions. These isolated cases indicate that while allergic reactions to titanium are theoretically possible, they occur so infrequently that they are considered outliers.

Reliable Allergy Testing:

If there are concerns about an individual's sensitivity to titanium, allergy testing can be performed. Patch testing, which involves applying small amounts of allergens to the skin, can help identify potential allergic reactions. However, it is important to note that patch testing for titanium sensitivity is not a routine procedure due to the rarity of allergic reactions. In cases where a true allergic reaction is suspected, specialized testing can be conducted to determine the specific cause of the reaction.

In summary, allergic reactions to titanium implants are extremely rare due to titanium's biocompatibility, low reactivity, and lack of allergenic potential. The minimal reports of allergic reactions, coupled with the stability and corrosion resistance of titanium implants, contribute to their overall safety and rarity of adverse responses. While allergy testing is available for individuals with specific concerns, it is not a standard practice due to the low incidence of allergic reactions to titanium.

The problem is you'll never know who is going to be sensitive and its a growing problem.